FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022193848> ?p ?o ?g. }

• W2022193848 endingPage "106" @default.
• W2022193848 startingPage "101" @default.
• W2022193848 abstract "33B.1, a rat IgG2a monoclonal antibody (MAb) directed against interleukin 2 receptor, has been given in association with prednisone and azathioprine to prevent rejection in 30 recipients of a primary cadaveric kidney transplant. The MAb 33B.1 had been administered intravenously (IV) at 10 mg per day for 2 weeks. Clinical and biological tolerance were excellent. Only one patient had a rejection episode (reversible) during the MAb treatment period. These results were significantly better than those recorded from a historical group of patients that received only prednisone and azathioprine, and were similar to those from patients who received antithymocyte globulin instead of 33B.1. There was no life threatening infectious episode and all patients are alive. Ninetyseven percent of the patients have a functional graft (follow-up, 30 to 210 days). Enzyme-linked immunosorbent assay (ELISA) of 33B.1 indicate that circulating trough blood level peaked at day 6 (30 nm). The majority of patients (85%) developed either IgG or IgM antibodies with a maximal response at day 24 for both isotypes. We conclude that this new treatment that targets a functional receptor present on activated lymphocytes only, is well tolerated and hiqhly efficient in preventing early rejection after human renal transplantation. 33B.1, a rat IgG2a monoclonal antibody (MAb) directed against interleukin 2 receptor, has been given in association with prednisone and azathioprine to prevent rejection in 30 recipients of a primary cadaveric kidney transplant. The MAb 33B.1 had been administered intravenously (IV) at 10 mg per day for 2 weeks. Clinical and biological tolerance were excellent. Only one patient had a rejection episode (reversible) during the MAb treatment period. These results were significantly better than those recorded from a historical group of patients that received only prednisone and azathioprine, and were similar to those from patients who received antithymocyte globulin instead of 33B.1. There was no life threatening infectious episode and all patients are alive. Ninetyseven percent of the patients have a functional graft (follow-up, 30 to 210 days). Enzyme-linked immunosorbent assay (ELISA) of 33B.1 indicate that circulating trough blood level peaked at day 6 (30 nm). The majority of patients (85%) developed either IgG or IgM antibodies with a maximal response at day 24 for both isotypes. We conclude that this new treatment that targets a functional receptor present on activated lymphocytes only, is well tolerated and hiqhly efficient in preventing early rejection after human renal transplantation." @default.
• W2022193848 created "2016-06-24" @default.
• W2022193848 creator A5005455170 @default.
• W2022193848 creator A5028469752 @default.
• W2022193848 creator A5040930081 @default.
• W2022193848 creator A5065766935 @default.
• W2022193848 creator A5071309303 @default.
• W2022193848 creator A5076808011 @default.
• W2022193848 creator A5080624263 @default.
• W2022193848 creator A5091402333 @default.
• W2022193848 date "1988-02-01" @default.
• W2022193848 modified "2023-09-24" @default.
• W2022193848 title "Prophylactic Use of a Monoclonal Antibody (33B3.1) Directed Against Interleukin 2 Receptor Following Human Renal Transplantation" @default.
• W2022193848 cites W1568092992 @default.
• W2022193848 cites W1981001323 @default.
• W2022193848 cites W1988368135 @default.
• W2022193848 cites W1993803666 @default.
• W2022193848 cites W2012014689 @default.
• W2022193848 cites W2071249922 @default.
• W2022193848 cites W2157953677 @default.
• W2022193848 doi "https://doi.org/10.1016/s0272-6386(88)80189-6" @default.
• W2022193848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3124608" @default.
• W2022193848 hasPublicationYear "1988" @default.
• W2022193848 type Work @default.
• W2022193848 sameAs 2022193848 @default.
• W2022193848 citedByCount "33" @default.
• W2022193848 crossrefType "journal-article" @default.
• W2022193848 hasAuthorship W2022193848A5005455170 @default.
• W2022193848 hasAuthorship W2022193848A5028469752 @default.
• W2022193848 hasAuthorship W2022193848A5040930081 @default.
• W2022193848 hasAuthorship W2022193848A5065766935 @default.
• W2022193848 hasAuthorship W2022193848A5071309303 @default.
• W2022193848 hasAuthorship W2022193848A5076808011 @default.
• W2022193848 hasAuthorship W2022193848A5080624263 @default.
• W2022193848 hasAuthorship W2022193848A5091402333 @default.
• W2022193848 hasConcept C126322002 @default.
• W2022193848 hasConcept C159654299 @default.
• W2022193848 hasConcept C163864487 @default.
• W2022193848 hasConcept C170493617 @default.
• W2022193848 hasConcept C203014093 @default.
• W2022193848 hasConcept C2776760755 @default.
• W2022193848 hasConcept C2777371288 @default.
• W2022193848 hasConcept C2778720950 @default.
• W2022193848 hasConcept C2779134260 @default.
• W2022193848 hasConcept C2780091579 @default.
• W2022193848 hasConcept C2780303639 @default.
• W2022193848 hasConcept C2911091166 @default.
• W2022193848 hasConcept C542903549 @default.
• W2022193848 hasConcept C71924100 @default.
• W2022193848 hasConceptScore W2022193848C126322002 @default.
• W2022193848 hasConceptScore W2022193848C159654299 @default.
• W2022193848 hasConceptScore W2022193848C163864487 @default.
• W2022193848 hasConceptScore W2022193848C170493617 @default.
• W2022193848 hasConceptScore W2022193848C203014093 @default.
• W2022193848 hasConceptScore W2022193848C2776760755 @default.
• W2022193848 hasConceptScore W2022193848C2777371288 @default.
• W2022193848 hasConceptScore W2022193848C2778720950 @default.
• W2022193848 hasConceptScore W2022193848C2779134260 @default.
• W2022193848 hasConceptScore W2022193848C2780091579 @default.
• W2022193848 hasConceptScore W2022193848C2780303639 @default.
• W2022193848 hasConceptScore W2022193848C2911091166 @default.
• W2022193848 hasConceptScore W2022193848C542903549 @default.
• W2022193848 hasConceptScore W2022193848C71924100 @default.
• W2022193848 hasIssue "2" @default.
• W2022193848 hasLocation W20221938481 @default.
• W2022193848 hasLocation W20221938482 @default.
• W2022193848 hasOpenAccess W2022193848 @default.
• W2022193848 hasPrimaryLocation W20221938481 @default.
• W2022193848 hasRelatedWork W2012014689 @default.
• W2022193848 hasRelatedWork W2022193848 @default.
• W2022193848 hasRelatedWork W2029562390 @default.
• W2022193848 hasRelatedWork W2056439492 @default.
• W2022193848 hasRelatedWork W2071647302 @default.
• W2022193848 hasRelatedWork W2401544240 @default.
• W2022193848 hasRelatedWork W2416726834 @default.
• W2022193848 hasRelatedWork W2417150169 @default.
• W2022193848 hasRelatedWork W2430221043 @default.
• W2022193848 hasRelatedWork W4299704392 @default.
• W2022193848 hasVolume "11" @default.
• W2022193848 isParatext "false" @default.
• W2022193848 isRetracted "false" @default.
• W2022193848 magId "2022193848" @default.
• W2022193848 workType "article" @default.